New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 11, 2013
08:04 EDTICAD, PHGiCAD, Invivo announce global strategic agreement for MRI solutions
Invivo, a Philips Healthcare Business (PHG), and iCAD, Inc. (ICAD) announced that the companies have entered into a global research, development, and commercial agreement. Under the agreement, iCAD will develop advanced MRI image analysis software products which Invivo will incorporate into its suite of MRI product solutions for global commercial sale. The first products are anticipated to be available in Q2 2013. The initial focus of the partnership will be the release of a next generation platform for prostate and breast imaging. Additional new product releases are also anticipated beginning the second half of 2013.
News For ICAD;PHG From The Last 14 Days
Check below for free stories on ICAD;PHG the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 24, 2014
08:03 EDTPHGPhilips receives FDA 510(k) clearance for mobile ultrasound system
Subscribe for More Information
July 23, 2014
13:33 EDTPHGWi-LAN enters into license agreement with Philips
Wi-LAN (WILN) announced that the company's subsidiary, Open Network Solutions, has entered into a license agreement with Philips (PHG) and Philips Electronics North America Corporation. The licensed patents relate to networking capabilities of non-standard devices. The remaining terms of the license agreement are confidential.
July 21, 2014
06:11 EDTPHGPhilips sees second half EBITA above last year
Subscribe for More Information
06:10 EDTPHGPhilips reports Q2 net income EUR 0.26 vs. EUR 0.35 last year
Reports Q2 revenue EUR 5.29B vs. EUR 5.63B last year. Healthcare comparable sales decreased 4%. Consumer Lifestyle comparable sales increased by 7%. Lighting comparable sales increased 1% year-on-year.
July 16, 2014
08:41 EDTICADiCAD shares recommended at Craig-Hallum
Craig-Hallum recommends buying iCAD following the announcement it acquired DermEbx and Radion. The firm views both transactions strategic and financially positive and reiterates its Buy rating and $16 price target.
07:19 EDTICADiCAD to host conference call
Subscribe for More Information
July 15, 2014
17:11 EDTICADiCAD acquires DermEbx, Radion for $12.6M in cash, stock
iCAD announced the signing of a definitive agreement to acquire DermEbx, an electronic brachytherapy services and technology provider, and Radion, a cloud-based oncology collaboration software solution. Total consideration at closing is approximately $12.6M, consisting of $3.8M in cash and 1.2M shares of iCAD common stock. The acquired companies are expected to be immediately accretive to revenues and operating cash flow. The current annual recurring revenue run-rate for DermEbx and Radion is $12M-$14M, with EBITDA margins greater than 25%. DermEbx and Radion currently service 23 locations with an active backlog of new customers. The acquisition closed July 15.
July 10, 2014
08:04 EDTPHGBofA/Merrill European capital goods analysts hold an conference call
The European Capital Goods Analyst Research Team provide a 2Q preview on an Analyst/Industry conference call to be held on July 10 at 9 am.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use